Empower Your Fight Against Bladder Cancer
Bladder cancer is highly recurrent and complex. Understand why securing your living urothelial tissue forms the absolute foundation for targeted genomic interventions and off-body drug testing.
Talk to a Care SpecialistWhat is Bladder Cancer?
Bladder cancer, or Urothelial Carcinoma, originates in the urothelial cells that line the inside of the bladder. It is heavily associated with environmental toxins and smoking.
It presents a dual challenge: non-muscle-invasive tumors are incredibly likely to recur constantly, while muscle-invasive tumors rapidly threaten systemic spread, requiring vastly different therapeutic strategies.
What Does Bladder Cancer Do?
Operating in the urinary tract, it severely impacts quality of life and visceral integrity.
- Urinary Hemorrhage: Tumors are friable and bleed easily, leading to significant, alarming blood in the urine.
- Muscle Wall Invasion: Deeply penetrating tumors breach the bladder's detrusor muscle, granting access to regional lymph nodes and surrounding pelvic organs.
- Constant Recurrence: The entirety of the urinary lining is exposed to the same toxins, meaning new tumors persistently "sprout" over time.
Current Treatment Options
TURBT & Intravesical Therapy
Scraping the tumor away internally followed by washing the inside of the bladder with chemotherapy or immunotherapy (BCG).
Radical Cystectomy
The complete surgical removal of the bladder, requiring the surgical construction of a new pathway for urine to leave the body.
Antibody-Drug Conjugates (ADCs)
Next-generation therapies that act as Trojan horses, using specialized antibodies to deliver chemotherapy directly inside urothelial cancer cells.
Why Bank Your Living Bladder Tissue?
Advances in bladder cancer have exploded with the discovery of targeted mutations (like FGFR) and the success of ADCs. When the bladder is removed, throwing away the tissue means discarding the precise biological map needed to match you with these incredibly potent, highly specific new drugs.
FGFR & Mutation Screening
Guaranteed access to living tissue means fail-safe sequencing for targetable mutations that dictate systemic therapy lines.
ADC Viability Testing
Expose your 3D-cultured urothelial cells to novel antibody-drug conjugates ex-vivo to prove they will bind and kill.
Organoid Cultivation
Establishing an organoid simulates the inner lining of your bladder, allowing repetitive off-body therapy trials.
Trial Passport
Solid tumor preservation instantly unlocks eligibility screening for the myriad of immune-oncology trials currently flooding urothelial cancer protocols.